The Japanese patent is a modest positive for NeuroThera's IP moat but does not change SciSparc's cash runway or clinical milestones. Monitor for any licensing agreements or partnership announcements that could monetize the patent. The stock's historical volatility suggests limited sustained reaction to such news.
Price Chart
Executive Summary
SciSparc's majority-owned subsidiary NeuroThera Labs was granted a Japanese patent for a proprietary combination of 4-aminophenol derivatives and N-acylethanolamines, intended to enhance analgesic and antipyretic therapies. The patent strengthens NeuroThera's IP portfolio but does not alter SciSparc's near-term financial outlook or clinical-stage status.
Key Facts
- NeuroThera Labs (TSXV: NTLX), a majority-owned subsidiary of SciSparc, received a Japanese patent for 'Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.'
- The patent covers combinations of 4-aminophenol derivatives (including paracetamol) and N-acylethanolamines to improve analgesic and antipyretic performance.
- No financial terms, revenue, or earnings data were disclosed in the filing.
- SciSparc's market capitalization is approximately $4M, and the company remains a clinical-stage pharmaceutical developer.
Financial Impact
No financial impact disclosed; patent grant is a non-revenue event with potential long-term IP value.
Risk Factors
- Patent does not guarantee commercial success or revenue generation.
- Clinical-stage biotech with no approved products; high cash burn risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (SPRC) — Batch item 1 | 0001213900-26-088078 |
| Document: ea030173602ex99-1.htm | 0001213900-26-088078 |
| Document: 0001213900-26-088078-index-headers.html | 0001213900-26-088078 |
| Document: 0001213900-26-088078-index.html | 0001213900-26-088078 |
| Document: 0001213900-26-088078.txt | 0001213900-26-088078 |
| 6-K Filing (SPRC) — Batch item 6 | 0001213900-26-088078 |
| Document: ea030173602ex99-1.htm | 0001213900-26-088078 |
| Document: 0001213900-26-088078-index-headers.html | 0001213900-26-088078 |
| Document: 0001213900-26-088078-index.html | 0001213900-26-088078 |
| Document: 0001213900-26-088078.txt | 0001213900-26-088078 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers